Nature reports how “[a] potential breakthrough in the quest to prevent HIV and AIDS has collided with sensitivities about testing expensive drugs in poor parts of the world.” A proposed clinical trial to test an experimental HIV therapy “in 3,000 African infants born to breastfeeding, HIV-infected mothers … is drawing fire from critics,” the journal writes, adding, “They cite the therapy’s steep cost and lack of proven efficacy in adults, and say that an affordable way to prevent mother-to-child HIV transmission already exists.” Nature continues, “Those points are likely to surface at a meeting in Entebbe, Uganda, on 22-23 January, where attendees will pound out principles for conducting prevention trials in breastfeeding babies born to HIV-positive mothers in poor countries.” The journal includes comments from several HIV researchers (Wadman, 1/16).